marketcaparena

Bright Minds Biosciences Inc.

DRUG · Figures in Canadian dollars

About Bright Minds Biosciences

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

brightmindsbio.com ↗

Employees
26
Business address
CHICAGO, IL
Fiscal year ends
September 30
Listed
Nasdaq · DRUG

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$51.66
−$1.06 (−2.01%)past year
Market cap
$394M
At close
Sep 28, 2026

Share price vs index

Bright Minds Biosciences's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Bright Minds Biosciences is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY25
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Operating leverage

FY25
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.